<DOC>
	<DOCNO>NCT01300468</DOCNO>
	<brief_summary>The purpose open-label , multi center , Phase I study determine safety profile oral compound PHA-848125AC administer accord two different schedule administration advanced/metastatic solid tumor patient . Objectives study determine maximum tolerate dose dose recommend Phase II investigation .</brief_summary>
	<brief_title>Study PHA-848125AC Adult Patients With Advanced/Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Signed , write IRBapproved Informed Consent Histologically cytologically confirm relapsed refractory solid tumor standard therapy exist ECOG ( WHO ) performance status 01 Life expectancy least 3 month Age &gt; =18 year A negative pregnancy test ( female reproductive year ) Acceptable liver renal function Acceptable hematologic status 10 . Previous cancer therapy allow exclusion experimental CDK2 inhibitor . Treatment radiation therapy , surgery , chemotherapy , investigational therapy must complete within one month prior study entry Use effective contraceptive method men woman child produce potential Capability swallow capsule intact Grade &lt; =1 retinopathy In past 6 month : myocardial infarction , unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis Known brain metastasis Major surgery , diagnostic surgery , within 4 week prior Day 1 Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Pregnant breast feed woman Unwillingness inability comply procedure require protocol Known infection HIV , active hepatitis B hepatitis C Diabetes mellitus uncontrolled , clinical evidence diabetic retinopathy , severe peripheral vascular disease diabetic ulcer Current enrollment another clinical trial Patients exhibit allergic reaction similar structural compound , biological agent , formulation ( lactose intolerance ) Previous history current presence neurological disorder , include epilepsy ( although control anticonvulsant therapy ) , Parkinson 's disease , multiple sclerosis , stroke cerebellar injury Gastrointestinal disease ( e.g . Crohn 's disease , ulcerative colitis , short gut syndrome ) would impact drug absorption Chronic/intensive use antacid H2 receptor antagonists Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study could compromise protocol objective opinion investigator and/or sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>advanced/metastatic solid tumor</keyword>
</DOC>